U.S. pharmaceutical group Merck is in advanced talks to acquire Acceleron Pharma, a move that would add drugs to treat rare diseases to Merck’s current pipeline.
The agreement could be finalized as soon as this week, The Wall Street Journal reported, citing people familiar with the move. The deal would value Acceleron at around $11 billion, or about $180 a share, and would be one of Merck’s biggest acquisitions.
Merck…
